Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIB101 in Advanced Solid Tumors
NCT05192174Phase 1Terminated
- Sponsor
- Noile-Immune Biotech Inc.
- Start
- Jan 2022
- Primary completion
- May 2025
- Modality
- Gene Editing, Gene Silencing, Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label trial of NIB101 in solid tumor (3 arms), sponsored by Noile-Immune Biotech Inc. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 2 years. Started Jan 2022; status: terminated.
02
Drugs
NIB101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05192174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05192174.